Grail (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Key Stats

• Today's Range: $14.68 to $15.48
• 50-Day Range: $12.57 to $15.92
• 52-Week Range: $12.33 to $23.36
• Volume: 481,166 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $507.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

GRAL Stock Analysis - Frequently Asked Questions

How have GRAL shares performed this year?

Grail's stock was trading at $14.57 at the start of the year. Since then, GRAL shares have increased by 3.6% and is now trading at $15.09.
View the best growth stocks for 2024 here.

How do I buy shares of Grail?

Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Grail own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Grail investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CUSIP: N/A
• CIK: 1699031
• Web: N/A
• Phone: (650) 771-9796
• Fax: N/A
• Employees: 1,360
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.65
• Quick Ratio: 9.65

Sales & Book Value

• Annual Sales: $117.67 million
• Price / Sales: 4.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,601,000
• Free Float: N/A
• Market Cap: $507.04 million
• Optionable: Optionable
• Beta: N/A